Soleno Therapeutics Target of Unusually Large Options Trading (NASDAQ:SLNO)

Soleno Therapeutics, Inc. (NASDAQ:SLNO) saw unusually large options trading on Monday. Stock traders bought 5,314 put options on the stock. This represents an increase of 109% compared to the average daily volume of 2,540 put options.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Analysts still rate the shares favorably — SLNO has a consensus rating of “Moderate Buy,” which could limit downside if the underlying business and trial program remain intact. Analyst Consensus
• Neutral Sentiment: Lead‑plaintiff deadline set for May 5, 2026; the alleged class period runs from March 26, 2025 through November 4, 2025 — investors with holdings in that window have until then to seek appointment. This is procedural but important for potential future litigation outcomes. Lawsuit Filing & Deadline
• Negative Sentiment: Class action filed alleging material misstatements/omissions regarding Soleno’s Phase 3 DCCR program — if plaintiffs prevail, the company could face significant financial exposure and reputational damage, creating near‑term downside risk. Class Action Allegations
• Negative Sentiment: Multiple plaintiff law firms (Robbins Geller, Kaplan Fox, Schall, DJS, Rosen and others) have issued notices encouraging investors to seek lead‑plaintiff status — the proliferation of firms amplifies media attention and selling pressure. Law Firm Notices

Soleno Therapeutics Stock Performance

NASDAQ SLNO traded up $0.65 during trading hours on Monday, hitting $34.41. 359,223 shares of the company’s stock traded hands, compared to its average volume of 1,618,233. Soleno Therapeutics has a 52 week low of $32.63 and a 52 week high of $90.32. The firm has a market capitalization of $1.78 billion, a P/E ratio of 149.59 and a beta of -3.16. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The business’s fifty day moving average price is $40.74 and its two-hundred day moving average price is $50.93.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million. Equities research analysts predict that Soleno Therapeutics will post -3.72 EPS for the current year.

Institutional Trading of Soleno Therapeutics

Hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC lifted its position in shares of Soleno Therapeutics by 12.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock valued at $134,270,000 after buying an additional 322,223 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Soleno Therapeutics during the fourth quarter valued at approximately $38,000. Seven Fleet Capital Management LP purchased a new position in Soleno Therapeutics during the fourth quarter valued at approximately $6,023,000. Virtu Financial LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter worth approximately $1,059,000. Finally, Empowered Funds LLC purchased a new stake in shares of Soleno Therapeutics in the fourth quarter worth $69,000. Institutional investors own 97.42% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on SLNO. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright dropped their target price on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. Finally, Wolfe Research set a $60.00 price target on Soleno Therapeutics in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $106.85.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.